Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate ... Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction ...